Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus HER STYLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus HER STYLE.
ASHLYNA vs HER STYLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
HER STYLE is a hormonal contraceptive containing ethinyl estradiol and levonorgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. It also thickens cervical mucus to impede sperm penetration and alters endometrial lining to prevent implantation.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
Not applicable. HER STYLE is not a recognized pharmaceutical agent; no standard dosing available.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal half-life: 12 hours (range 10–14 hours). Clinical context: Allows twice-daily dosing; steady-state achieved in ~2.5 days.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10%.
Category C
Category C
Contraceptive
Contraceptive